Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
05/18/20177:05AMGLOBEMyriad Genetics to Present Seven Studies at the 2017 American Society of Clinical Oncology Annual Meeting
SALT LAKE CITY, May 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from seven studies at the 2017 American Society of Clinical Oncology (ASCO) annual meeting to be held June 2 to 6, 2016 in Chicago... More...>>
05/12/20177:05AMGLOBEMyriad Genetics’ Prolaris® Test Accurately Predicts the 10-Year Risk of Metastases in Men Treated for Prostate Cancer
SALT LAKE CITY, May 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to accurately predict the 10-year risk of metastases in men treated for prostate cancer. The data are... More...>>
05/08/20173:03AMDJNDon't Give Up on Stock Buybacks, At Least Not Yet -- WSJ
The programs are no longer a sure thing -- but there's still an effect on value stocks By Mark Hulbert Stock buybacks are no longer considered an unambiguously good thing, for companies or investors. But investors might still be able to profit from them. As recently as the 1990s, the market typically celebrated a... More...>>
05/05/20177:05AMGLOBEMyriad Genetics to Present Results from Four Studies at the American Urological Association 2017 Annual Meeting
SALT LAKE CITY, May 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from four separate prostate cancer studies at the American Urological Association (AUA) 2017 Annual Meeting being held May 12-16... More...>>
05/02/20174:05PMGLOBEMyriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results
Third-Quarter 2017 Total Revenues of $196.9 MillionThird-Quarter 2017 GAAP Diluted EPS of $0.06 and Adjusted EPS of $0.27Company Increases Annual Revenue Guidance, Narrows Adjusted EPS Guidance SALT LAKE CITY, May 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics... More...>>
04/27/20177:05AMGLOBEMyriad Genetics and Clovis Oncology Sign Agreement for Use of FDA-Approved BRACAnalysis CDx® Test to Identify Patients with ...
SALT LAKE CITY and BOULDER, Colo., April 27, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) and Clovis Oncology, Inc. (NASDAQ:CLVS) today announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibitor, Rubraca.  Financial terms of... More...>>
04/18/20174:05PMGLOBEMyriad to Announce Fiscal Third-Quarter 2017 Financial Results on May 2, 2017
SALT LAKE CITY, April 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal third-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, May 2, 2017.  During the call, Mark C. Capone, president and CEO and Bryan... More...>>
04/17/20177:05AMGLOBEStudy Finds Wide Gap in Quality of BRCA1/2 Variant Classification Between Myriad Genetics and A Common Public Database
SALT LAKE CITY, April 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that new data comparing BRCA1 and BRCA2 variant classifications between Myriad Genetics and a commonly used public genetic database was published in the journal... More...>>
04/06/20177:05AMGLOBEMyriad Genetics and BeiGene Sign Agreement to Develop Companion Diagnostics for Use with BeiGene’s Novel PARP Inhibitor, BG...
SALT LAKE CITY, April 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has entered into a companion diagnostic development collaboration with BeiGene, a clinical-stage biopharmaceutical company developing molecularly-targeted... More...>>
04/05/20177:05AMGLOBEPivotal Study Results for Myriad’s myPath® Melanoma Test Highlighted In Two Additional Scientific Publications
SALT LAKE CITY, April 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has published the third clinical validation study and second clinical utility study for its myPath® Melanoma test, which completes the reimbursement... More...>>
03/20/20177:05AMGLOBEMyriad Genetics Announces Five Scientific Presentations at the 2017 American College of Medical Genetics Annual Clinical Gene...
SALT LAKE CITY, March 20, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the company will present five scientific posters at the 2017 American College of Medical Genetics Annual Clinical Genetics Meeting in Phoenix, AZ. ... More...>>
03/13/20177:05AMGLOBEMyriad Genetics Launches the EndoPredict® Test in the United States for Patients with Breast Cancer
SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it has launched the EndoPredict® test in the United States for patients with ER+ HER2- early-stage breast cancer.  EndoPredict is a second-generation... More...>>
02/23/20177:05AMGLOBEGeneSight® Psychotropic Test Demonstrated Substantial Cost Savings for Payers in New Study Published in Clinical Therapeutic...
SALT LAKE CITY, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that new data on the use of the GeneSight® Psychotropic test to deliver medication cost savings for mental health disorders was published in the journal Clinical Therapeutics.[1] ... More...>>
02/17/20177:30AMGLOBEMyriad’s BRACAnalysis CDx® Test Successfully Identified Metastatic Breast Cancer Patients with Improved Outcomes from Astr...
SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new findings from the OlympiAD study that show its BRACAnalysis CDx®  test successfully identified patients with HER2-negative metastatic breast cancer... More...>>
02/17/20177:05AMGLOBEMyriad’s Prolaris® Test Significantly Improves the Risk Classification for One Third of Men Diagnosed with Localized Prost...
SALT LAKE CITY, Feb. 17, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data demonstrating the utility of the Prolaris® test to more accurately classify mortality risk and guide the management of newly diagnosed men with prostate cancer. The... More...>>
02/10/20175:47PMPRNUSMyriad Genetics to Join S&P SmallCap 600
Myriad Genetics to Join S&P SmallCap 600 PR Newswire NEW YORK, Feb. 10, 2017 NEW YORK, Feb. 10, 2017 /PRNewswire/ -- Myriad Genetics, Inc. (NASD: MYGN) will replace Inteliquent, Inc. (NASD: IQNT) in the S&P SmallCap 600 after the close on Tuesday, February 14. GTCR LLC has acquired Inteliquent in a deal expected... More...>>
02/07/20174:05PMGLOBEMyriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results
Second-Quarter 2017 Total Revenues of $196.5 MillionSecond-Quarter 2017 GAAP Diluted EPS of $0.09 and Adjusted EPS of $0.26Company Updates Fiscal Year 2017 Guidance and Issues Fiscal Third-Quarter 2017 Guidance SALT LAKE CITY, Feb. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular... More...>>
01/24/20174:05PMGLOBEMyriad to Announce Fiscal Second-Quarter 2017 Financial Results on February 7, 2017
SALT LAKE CITY, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will hold its fiscal second-quarter 2017 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, February 7, 2017.  During the call, Mark C. Capone, president and CEO and... More...>>
01/06/20177:05AMGLOBEThe EndoPredict® Test Receives Positive Coverage Decisions from Multiple Blue Cross Blue Shield Affiliate Plans
SALT LAKE CITY, Jan. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that multiple Blue Cross Blue Shield (BCBS) affiliate plans have issued positive coverage determinations for EndoPredict®, including Independence Blue Cross, Blue Cross and Blue... More...>>
01/05/20177:05AMGLOBEEndoPredict® Reviewed by Blue Cross Blue Shield Association’s Evidence Street
SALT LAKE CITY, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in personalized medicine, today announced that Evidence Street has reviewed EndoPredict®, Myriad’s second-generation test to predict breast cancer recurrence, and determined that the test results in a meaningful improvement... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20170523 16:40:41